• Monday,
  7/27
• Tuesday,
  7/28
• Wednesday,
  7/29
• Thursday,
  7/30
• Friday,
  7/31

Dementia and Cognitive Health in LGBTQ Older Adults

Session Chairs: Maria M. Corrada, Ozioma Okonkwo

• Interventions for LGBTQ Older Adults With ADRD and Their Care Partners
  Karen Fredriksen-Goldsens, University of Washington, United States
• The Epidemiology of ADRD in LGBTQ Older Adults
  Jason Flatt, University of Nevada, Las Vegas; University of California, San Francisco, San Francisco, United States
• LGBTQ Older Adults With Cognitive Impairment: Implications for Early Diagnosis, Treatment and Care
  Sue Westwood, University of York, United Kingdom
• Sociolegal and Practice Implications of Caring for LGBTQ People With Dementia
  Rosie Harding, Birmingham Law School, United Kingdom

Ethics in Dementia

Session Chairs: Frank Jessen, Carey Gleason

• Ethical and Practical Challenges in Disclosure of APOE Genotype
  J. Scott Roberts, University of Michigan, United States
• Expectations and Effects of Biomarker-Based Dementia Risk Prediction in MCI — The PreDaDQual Project
  Ayda Rostamzadeh, University of Cologne, Germany
• Ethical Considerations on Individualized Risk Prediction in MCI — The ABIDE Project
  Jetske van der Schaar, Amsterdam UMC, Netherlands
• Amyloid Disclosure in Mild Cognitive Impairment
  Jennifer Lingler, University of Pittsburgh, United States

Immunity in The Aging or Diseased Brain

Session Chairs: Sergio Ferreira, Jose F. Abisambra

• The Bidirectional Communication Between the Brain and the Systemic Immune System in Aging
  Marina Lynch, Trinity College Institute of Neuroscience, Ireland
• Trem2- Independent Activity of PD-L1 Immunotherapy in Modifying Alzheimer’s Disease in Mouse Models
  Michal Schwartz, Weizmann Institute of Science, Israel
• Microglial Immune Memory and Metabolic Reprogramming Modifies Amyloid Structure and Neuronal Dystrophy in Mouse Models of Alzheimer’s Pathology
  Jonas Neher, German Center for Neurodegenerative Diseases (DZNE); Hertie Institute for Clinical Brain Research, Germany

Measuring Tau Accumulation and Progression

Session Chairs: Kejal Kantarci, Brad Dickerson

• Tau Progression Evidence From Tau PET Imaging
  Rik Ossenkoppele, Alzheimer Center Amsterdam; Vrije Universiteit Amsterdam, Amsterdam UMC, Netherlands; Lund University, Sweden
• Pathologic Progression of Tau
  Gabor Kovacs, University of Toronto, Canada
• Multi-omic Approach to Tau Accumulation and Progression
  Philip De Jager, Columbia University Medical Center, United States
• Interaction of Tau With Other Pathologies
  Virginia Lee, Perelman School of Medicine at the University of Pennsylvania, United States

Mechanisms of White Matter Damage

Session Chairs: Roxana Carare, Delphine Boche

• Understanding the Pathophysiology of Amyloid-Related Imaging Abnormalities (ARIA) Following Aβ Immunotherapy
  James Nicoll, University of Southampton, United Kingdom
• Biomarkers of Vascular Cognitive Impairment and Dementia; Informing Disease Mechanisms
  Donna Wilcock, University of Kentucky Sanders Brown Center on Aging, United States
• Trauma-Related Axonal Damage
  Victoria Johnson, University Of Pennsylvania, United States
• Neuroimaging of White Matter Hyperintensities (WMH)
  Joanna Wardlaw, University of Edinburgh, United Kingdom

Repurposing Drugs Targeting Glia and Inflammatory Mechanisms

Session Chairs: Linda Van Eldik, Cynthia Lemere

• Targeting solTNF to Reduce Risk and Progression of Alzheimer’s Disease and Other Dementias
  Malú Tansey, University of Florida College of Medicine, United States
• Repurposing Senotlytic Therapies for Alzheimer’s Disease
  Howard Fillit, Alzheimer’s Drug Discovery Foundation, United States
• Microglial Cells in AD: Good Guys or Bad Guys?
  Knut Biber, AbbVie Deutschland GmbH & Co. KG, Germany
• Finding New Uses for Old Drugs in Alzheimer’s Disease
  Clive Ballard, University of Exeter Medical School, United Kingdom

Towards a Precision Medicine Approach in Alzheimer’s Disease

Session Chairs: Jonathan Schott, Wiesje van Der Flier

• Blood-Based Biomarkers to Predict Current and Future Alzheimer’s Disease
  Randall Bateman, Washington University in St. Louis School of Medicine, United States
• Accurate Prediction of β-Amyloid Positivity Using Risk Models and Plasma Aβ and P-tau Analyses
  Sebastian Palmqvist, Lund University; Skåne University Hospital, Sweden
• Biomarker-Based Prognosis for People With Mild Cognitive Impairment
  Ingrid van Maurik, Alzheimer Center Amsterda; Vrije Universiteit Amsterdam, Amsterdam UMC, Netherlands
• Organizing Mechanistic Knowledge About Neurodegenerative Diseases for the Improvement of Drug Development and Therapy
  Martin Hofmann-Apitius, Fraunhofer Institute for Algorithms and Scientific Computing (SCAI), Sankt Augustin; Bonn-Aachen International Center for IT (b-it), Germany

Using Technology to Improve Access to Cognitive Assessments and Interventions

Session Chairs: Maureen Schmitter-Edgecombe, Rema Raman

• Unsupervised Online Neuropsychological Testing — The Principles
  Paul Maruff, The Florey Institute of Neuroscience and Mental Health, Australia
• Establishing Psychometric Properties and Normative Data for Technology
  Heleen Feenstra, University of Amsterdam, Netherlands
• Socially Assistive Robots for Cognitive and Social Stimulation
  Jesus Favela, CICESE Research Center, Mexico
• Testing on Mobile Devices
  Simon Collinson, Savonix, Singapore